Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals' stock price has experienced significant fluctuations over the past six months. On November 7, 2025, the stock plunged due to mixed results from the BESTOW clinical trial. On November 12, 2025, the stock fell again in premarket trading. On November 14, 2025, Eledon reported its Q3 2025 earnings, exceeding EPS estimates. On November 18, 2025, the stock rose in after-hours trading, but Guggenheim lowered its target price. In November 2025, the company announced a dilutive public offering. On December 29, 2025, Weiss Ratings reaffirmed a sell rating. On December 30, 2025, the stock closed up following news of a stock exchange agreement. On January 2, 2026, the stock continued its positive momentum. On January 7, 2026, shares were trading up due to technical momentum. On January 12, 2026, the stock rose on positive preliminary results and the announcement of a public offering. Overall, the company's share price experienced a significant decline between January 13, 2025, and January 9, 2026.

As a clinical-stage biotechnology company, Eledon Pharmaceuticals, Inc. does not produce commercialized products or services that are subject to traditional demand seasonality. The company's focus is on research and development, particularly advancing its lead compound, tegoprubart, through clinical trials. Therefore, its demand is primarily driven by investor interest, clinical milestones, regulatory progress, and the overall sentiment towards the biotechnology sector.

Eledon Pharmaceuticals, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing immunology-driven therapies. Their primary focus is on the CD40 Ligand pathway, with their lead product candidate, tegoprubart, being evaluated in multiple Phase 2 clinical settings. The company aims to translate a validated immunologic target into differentiated therapies for high-need indications, supported by collaborations.

Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California, in the United States. While its base of operations is in the U.S., the company conducts global clinical trials for its lead product candidate, tegoprubart.

Eledon Pharmaceuticals' brand reputation has been shaped by its clinical trial outcomes and financial activities. The mixed results from the Phase 2 BESTOW trial significantly impacted investor confidence. Positive preliminary data from other studies and successful public offerings have provided some positive momentum. Analyst ratings reflect varying perceptions of the company's prospects. Its reputation is largely tied to the progress of its drug development programs and its ability to secure funding.

Eledon Pharmaceuticals, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional shareholders hold a significant portion of the company's stock. Insiders own a notable percentage of the shares. Retail investors hold a portion of the stock. Major institutional owners include Bvf Inc/il, Ra Capital Management, L.p., BlackRock, Inc., Vanguard Group Inc, Siren, L.L.C., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Zimmer Partners, LP, Geode Capital Management, Llc, Wellington Management Group Llp, and Sphera Funds Management Ltd. BVF Partners L.P. is a large shareholder. Seth Loring Harrison is the largest individual shareholder. James N. Topper also owns a substantial number of shares.